DA Davidson Upgrades Oracle to Buy, $180 Price Target
DA Davidson upgrades Oracle to Buy, citing strong OpenAI outlook and reduced risks, with a $180 price target.
Already have an account? Sign in.
DA Davidson upgrades Oracle to Buy, citing strong OpenAI outlook and reduced risks, with a $180 price target.
Company raised shareholder returns with $10B buyback plan.
Repligen to acquire BioLife Solutions in a $1.5B cash-and-stock deal to strengthen its position in the fast-growing cell and gene therapy market. Expected to close Q4 2026.
Dyne Therapeutics announced the pricing of an upsized $375 million public stock offering at $20.50 per share to advance DMD and DM1 programs and extend cash runway into 2029.